Recent advances in detection techniques regarding predictive, prognostic, and diagnostic biomarkers in solid cancers and its future challenges.

Abstract

The advent of biomarker-driven strategies has focused research on early detection, accurate diagnosis, prognosis assessment, and personalized treatment, thus revolutionizing the landscape of cancer care. The current chapter gives an extensive review of the latest advances in predictive, prognostic, and diagnostic biomarker detection methods in solid tumors using advanced technologies such as liquid biopsy, circulating tumor DNA (ctDNA), microRNAs, exosomal profiling, and multi-omics platforms that have high specificity and sensitivity in the identification of biomarkers. Additionally, the application of artificial intelligence and machine learning in biomarker analysis has showcased its ability to facilitate improved clinical decision-making. In addition, the chapter explores the clinical usefulness of these biomarkers in different solid cancers like breast, lung, colorectal, and prostate cancers. Despite the well-paced development in these fields, issues like tumor heterogeneity, cross-validation in different populations, and translating emerging biomarkers into everyday clinical practice still persist. The chapter concludes by describing future horizons and the imperative of strong standardization, interdisciplinarity, and ethics in applying biomarker-based approaches in oncology. As precision oncology advancements are on the rise, the integration of real-time biomarker monitoring and minimally invasive techniques holds promise for dynamic disease management. Emerging technologies like single-cell sequencing and spatial transcriptomics further enhance our understanding of tumor biology, paving the way for more individualized and adaptive therapeutic interventions in solid cancer treatment. Collaborative efforts between academia, industry, and clinical settings are essential to accelerate biomarker validation and regulatory approval, ensuring equitable access to advanced diagnostic tools across diverse patient populations worldwide.